\begin{longtable}{p{0.3\textwidth}p{0.2\textwidth}p{0.2\textwidth}p{0.2\textwidth}}
   & Ozempic & Wegovy & Mounjaro \\ 
  \hline 
\endfirsthead 
\multicolumn{4}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & Ozempic & Wegovy & Moujaro\\ \hline 
\endhead 
\hline \multicolumn{4}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=9464) & (N=4884) & (N=4741) \\ 
  Age &  &  &  \\ 
    Mean (SD) & 57 (13) & 48 (12) & 52 (13) \\ 
  Age Group &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 1783 (19\%) & 1919 (39\%) & 1362 (29\%) \\ 
    45-64 & 4811 (51\%) & 2517 (52\%) & 2585 (55\%) \\ 
    65+ & 2870 (30\%) & 448 (9\%) & 794 (17\%) \\ 
  Sex &  &  &  \\ 
    Female & 6186 (65\%) & 4040 (83\%) & 3376 (71\%) \\ 
    Male & 3272 (35\%) & 843 (17\%) & 1363 (29\%) \\ 
    Unknown & 6 (0\%) & 1 (0\%) & 2 (0\%) \\ 
  Race &  &  &  \\ 
    White & 6866 (73\%) & 3464 (71\%) & 3587 (76\%) \\ 
    Black & 1530 (16\%) & 885 (18\%) & 600 (13\%) \\ 
    Asian & 208 (2\%) & 65 (1\%) & 70 (1\%) \\ 
    AI or AN & 58 (1\%) & 30 (1\%) & 22 (0\%) \\ 
    NH or PI & 29 (0\%) & 16 (0\%) & 8 (0\%) \\ 
    Other Race & 425 (4\%) & 256 (5\%) & 305 (6\%) \\ 
    Declined to answer & 96 (1\%) & 38 (1\%) & 43 (1\%) \\ 
    Unknown & 252 (3\%) & 130 (3\%) & 106 (2\%) \\ 
  Ethnicity &  &  &  \\ 
    Hispanic or Latino & 883 (9\%) & 493 (10\%) & 552 (12\%) \\ 
    Not Hispanic or Latino & 8126 (86\%) & 4165 (85\%) & 3969 (84\%) \\ 
    Declined to answer & 130 (1\%) & 54 (1\%) & 41 (1\%) \\ 
    Unknown & 325 (3\%) & 172 (4\%) & 179 (4\%) \\ 
  T2D & 5762 (61\%) & 284 (6\%) & 2274 (48\%) \\ 
  Obesity or Overweight & 8056 (85\%) & 4655 (95\%) & 4203 (89\%) \\ 
  Period &  &  &  \\ 
    2018 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2018 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2019 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2019 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2020 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2020 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2021 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2021 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2022 Jan-Jun & 609 (6\%) & 163 (3\%) & 34 (1\%) \\ 
    2022 Jul-Dec & 3272 (35\%) & 739 (15\%) & 2173 (46\%) \\ 
    2023 Jan-Jun & 5583 (59\%) & 3982 (82\%) & 2534 (53\%) \\ 
    2023 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
  Atrial Fibrilation & 689 (7\%) & 153 (3\%) & 234 (5\%) \\ 
  Asthma & 1822 (19\%) & 1021 (21\%) & 933 (20\%) \\ 
  CKD & 1311 (14\%) & 189 (4\%) & 396 (8\%) \\ 
  COPD & 737 (8\%) & 153 (3\%) & 221 (5\%) \\ 
  Glaucoma & 217 (2\%) & 42 (1\%) & 69 (1\%) \\ 
  Heart Failure & 807 (9\%) & 131 (3\%) & 229 (5\%) \\ 
  Hyperlipidemia & 6422 (68\%) & 2405 (49\%) & 2867 (60\%) \\ 
  Hypertension & 6541 (69\%) & 2347 (48\%) & 2914 (61\%) \\ 
  Ischemic Heart Disease & 798 (8\%) & 137 (3\%) & 249 (5\%) \\ 
  Acute MI & 339 (4\%) & 56 (1\%) & 101 (2\%) \\ 
  Ischemic Stroke & 35 (0\%) & 4 (0\%) & 6 (0\%) \\ 
  Major Depressive Disorder & 1852 (20\%) & 1111 (23\%) & 987 (21\%) \\ 
  Osteoporosis & 327 (3\%) & 107 (2\%) & 131 (3\%) \\ 
  Bariatric Surgery & 262 (3\%) & 272 (6\%) & 160 (3\%) \\ 
  Metformin & 4372 (46\%) & 452 (9\%) & 1895 (40\%) \\ 
  SGLT2i & 1565 (17\%) & 43 (1\%) & 580 (12\%) \\ 
  DPP4 & 824 (9\%) & 9 (0\%) & 317 (7\%) \\ 
  Sulfonylurea & 1420 (15\%) & 12 (0\%) & 480 (10\%) \\ 
  Insulin & 679 (7\%) & 89 (2\%) & 273 (6\%) \\ 
  Orlistat & 11 (0\%) & 10 (0\%) & 7 (0\%) \\ 
  Phentermine Topiramate & 28 (0\%) & 64 (1\%) & 43 (1\%) \\ 
  BMI &  &  &  \\ 
    Mean (SD) & 37 (8.4) & 39 (8.2) & 38 (8.4) \\ 
    Missing & 4789 (50.6\%) & 2588 (53.0\%) & 2337 (49.3\%) \\ 
  Weight (in lbs) &  &  &  \\ 
    Mean (SD) & 240 (57) & 230 (53) & 240 (57) \\ 
    Missing & 2968 (31.4\%) & 1618 (33.1\%) & 1239 (26.1\%) \\ 
  HbA1c &  &  &  \\ 
    Mean (SD) & 7.2 (1.8) & 5.6 (0.51) & 6.8 (1.6) \\ 
    Missing & 3537 (37.4\%) & 2487 (50.9\%) & 1734 (36.6\%) \\ 
  \hline
\caption{Characteristics of patients first prescribed a GLP-1 RA in May 2022 or later, for Ozempic, Wegovy, and Mounjaro.\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_brand_postMay22}
\end{longtable}
